dr. burtness on findings of keynote-048 in head and neck cancer
Published 5 years ago • 659 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
1:52
dr. burtness on promise of frontline pembrolizumab in metastatic hnscc
-
1:43
dr. burtness on ongoing trials of immunotherapy in head and neck cancer
-
1:35
dr. burtness on emerging immunotherapies in head and neck cancer
-
1:23
dr. burtness on the benefit of pembrolizumab in head and neck cancer
-
1:05
dr. burtness on combinations of immunotherapy in head and neck cancer
-
1:57
dr. burtness on the future of immunotherapy in head and neck cancer
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
1:34
dr. burtness on frontline immunotherapy in head and neck cancer
-
1:00
dr. burtness on immunotherapy and radioresistance in head and neck cancer
-
1:22
dr. burtness on immunotherapy and chemotherapy in head and neck cancer
-
1:03
dr. burtness on the use of immunotherapy after chemoradiation in head and neck cancer
-
1:30
dr. burtness on immunotherapy resistance in head and neck cancer
-
1:40
dr. burtness on the use of biomarkers in metastatic hnscc
-
1:52
dr. burtness on the development of immunotherapy in head and neck cancers
-
1:29
dr. burtness on challenges facing immunotherapy in head and neck cancer
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
7:56
keynote-048: progression post next line for r/m hnscc
-
5:48
the impact of systemic therapy and keynote-048 trial